和邦生物(603077.SH):一季度淨利預增302.72%-338.60%
格隆匯4月11日丨和邦生物(603077.SH)公佈2022年第一季度業績預增公吿,公司預計2022年第一季度實現歸屬於上市公司股東的淨利潤為10.1-11億元,與上年同期相比增加7.59-8.49億元,同比增加302.72%-338.60%。
扣除非經常性損益事項後,公司預計2022年第一季度實現歸屬於上市公司股東的扣除非經常性損益的淨利潤為10.1-11億元,與上年同期相比,將增加7.607-8.507億元,同比增加305.18%-341.28%。
業績預盈主要原因是:(一)產品銷售價同比提升1、公司主要產品氯化銨(主要用於生產複合肥)價格同比漲幅較大,創近年來新高;2、公司主要產品純鹼、雙甘膦/草甘膦價格較去年同期有較大提升。
(二)公司第二期員工持股計劃於2022年1月通過非交易過户完成,根據《企業會計準則第11號---股份支付》,預計2022年第一季度因該事項需確認的費用約為1.04億元,計入本報吿期損益。
(三)公司在“專注、專業、做優、做強”的發展戰略指導下,不斷通過自主技術創新,工藝革新、引進先進技術等措施和手段,實現了成本控制水平的持續提升,為公司獲得良好的盈利空間創造了技術條件。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.